Hepatocellular Carcinoma Associated with Hepatic Sarcoidosis and Budd-Chiari Syndrome: A Case Report and Review of the Literature.

Intern MedFeb 24, 2026 (epub)

Yuta Minami, Takanobu Iwadare, Yuma Kamijo et al.

✦ AI-curated · Sources linked

Case in brief

A 71-year-old woman with cutaneous sarcoidosis presented with hepatocellular carcinoma. Evaluation identified Budd-Chiari syndrome, indicating hepatic venous outflow obstruction, and hepatic granulomas with advanced fibrosis. The report describes HCC in the setting of both hepatic sarcoidosis and Budd-Chiari syndrome; the abstract does not report treatment or subsequent outcome.

What made this case unusual

The notable finding was HCC occurring alongside hepatic sarcoidosis and Budd-Chiari syndrome, a coexistence the authors describe as extremely rare and not previously reported with HCC.

Diagnostic / clinical pearl

In a patient with sarcoidosis and HCC, assess for hepatic involvement and venous outflow obstruction; this case documented both hepatic granulomas with advanced fibrosis and Budd-Chiari syndrome.

Why it matters

The authors suggest hepatic sarcoidosis and Budd-Chiari syndrome may contribute additively or synergistically to a pro-carcinogenic hepatic environment, though a single case cannot establish causation.

Source

Published in Intern Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.